Disease · MONDO_0006314
nasal cavity polyp
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. nasal cavity polyp. Diseases, record MONDO_0006314. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006314
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEPEMOKIMAB | CHEMBL4650469 | Antibody | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| FLUTICASONE PROPIONATE | CHEMBL1473 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MOMETASONE FUROATE | CHEMBL1161 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIMEGEPANT | CHEMBL2178422 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BECLOMETHASONE DIPROPIONATE | CHEMBL1200500 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BISOPROLOL | CHEMBL645 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets15
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Approval | https://conductscience.org/library/genes/3567 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Phase 2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| AVPR1A | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2 | https://conductscience.org/library/genes/552 | Drugs and targets |
| AVPR1B | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2 | https://conductscience.org/library/genes/553 | Drugs and targets |
| AVPR2 | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2 | https://conductscience.org/library/genes/554 | Drugs and targets |
| CALCRL | Calcitonin gene-related peptide type 1 receptor | 1 | Calcitonin gene-related peptide type 1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/10203 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Phase 3 | https://conductscience.org/library/genes/3566 | Drugs and targets |
| IL5RA | Interleukin-5 receptor subunit alpha | 1 | Interleukin-5 receptor subunit alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/3568 | Drugs and targets |
| MMP1 | Interstitial collagenase | 1 | Matrix metalloproteinase-1 inhibitor | Phase 2 | https://conductscience.org/library/genes/4312 | Drugs and targets |
1 to 10 of 15
See all 15 targetsTrials22
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01386125 | A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604) | Phase 3 | 748 | 2013-12-19 | Nasal Polyps | MOMETASONE FUROATE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01623323 | Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps | Phase 3 | 705 | 2016-03-01 | Chronic Sinusitis With or Without Nasal Polyps | FLUTICASONE PROPIONATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02898454 | Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps | Phase 3 | 448 | 2019-10-23 | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | DUPILUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03085797 | Effect of Mepolizumab in Severe Bilateral Nasal Polyps | Phase 3 | 414 | 2020-12-17 | Nasal Polyps | MEPOLIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03401229 | Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis | Phase 3 | 413 | 2021-10-12 | Nasal Polyposis | BENRALIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT04157335 | Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) | Phase 3 | 295 | 2026-02-19 | Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | BENRALIZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT05248997 | Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis | Phase 3 | 261 | 2025-03-26 | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | RIMEGEPANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01623310 | 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device | Phase 3 | 223 | 2018-01-24 | Nasal Polyps | FLUTICASONE PROPIONATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00378378 | Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292) | Phase 3 | 127 | 2010-07-20 | Nasal Polyps | MOMETASONE FUROATE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01732536 | Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps | Phase 2/3 | 100 | 2018-07-20 | Chronic Sinusitis, Nasal Polyps | MOMETASONE FUROATE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| MFNS vs Placebo: serious adverse events | 2 of 375 | 3 of 373 | 748 | NCT01386125 | Trial comparisons |
| Benra 30 mg vs Placebo: Percentage of Subjects With NP Surgery or SCS_NP | 72 of 207 | 91 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: Percentage of Subjects With NP Surgery | 33 of 207 | 37 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: deaths from any cause | 0 of 207 | 0 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: Percentage of Subjects With SCS_NP | 52 of 207 | 66 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: serious adverse events | 25 of 207 | 19 of 203 | 410 | NCT03401229 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP | 26 of 139 | 30 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery for CRSwNP | 8 of 139 | 10 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With SCS Use for CRSwNP | 21 of 139 | 22 of 135 | 274 | NCT04157335 | Trial comparisons |
| Rimegepant vs Placebo: deaths from any cause | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials41
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006314
GET https://conductscience.org/api/diseases/v1/MONDO_0006314/trials?page=2